Treace Medical Concepts, INC Form 4 insider transactions

Director Deepti Jain of Treace Medical Concepts, Inc. (TMCI) recently purchased 25,000 shares of common stock at a price of $4.5027 per share.

Director Richard Mott increased his holdings in Treace Medical Concepts through open market purchases.

Director James T. Treace recently acquired a significant number of Treace Medical Concepts shares, signaling confidence in the company's future.

Director John K. Bakewell of Treace Medical Concepts, Inc. reports the acquisition of 130,000 shares of common stock at an average price of $4.574 on May 10, 2024.

CEO John T. Treace recently acquired 300,000 shares of Treace Medical Concepts (TMCI) through open market purchases.

Director James Treace sold shares of Treace Medical Concepts (TMCI) on November 15, 2022, under a pre-arranged Rule 10b5-1 trading plan.

Aaron Berutti, SVP of Sales at Treace Medical Concepts, disposed of shares to satisfy tax withholding obligations related to the vesting of restricted stock units.

Mark Hair, CFO of Treace Medical Concepts, reports disposing of shares to cover tax obligations related to restricted stock units.

CEO John T. Treace of Treace Medical Concepts, Inc. reports disposing of shares to cover tax obligations related to restricted stock units.

Sean Scanlan, Chief Innovation Officer of Treace Medical Concepts, reports disposing of common stock to cover tax obligations related to restricted stock units.

Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary of Treace Medical Concepts, Inc., reported the disposal of common stock to cover tax obligations related to restricted stock units.